15.95
price down icon8.39%   -1.46
pre-market  プレマーケット:  16.39   0.44   +2.76%
loading
前日終値:
$17.41
開ける:
$17.12
24時間の取引高:
227.77K
Relative Volume:
2.67
時価総額:
$149.75M
収益:
-
当期純損益:
$-81.17M
株価収益率:
-1.5738
EPS:
-10.1344
ネットキャッシュフロー:
$-82.84M
1週間 パフォーマンス:
-21.74%
1か月 パフォーマンス:
-36.38%
6か月 パフォーマンス:
-51.67%
1年 パフォーマンス:
-82.23%
1日の値動き範囲:
Value
$15.63
$17.82
1週間の範囲:
Value
$15.16
$20.80
52週間の値動き範囲:
Value
$15.16
$98.00

Korro Bio Inc Stock (KRRO) Company Profile

Name
名前
Korro Bio Inc
Name
セクター
Healthcare (1165)
Name
電話
617-468-1999
Name
住所
60 FIRST STREET, CAMBRIDGE
Name
職員
104
Name
Twitter
Name
次回の収益日
2024-12-08
Name
最新のSEC提出書
Name
KRRO's Discussions on Twitter

KRRO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KRRO
Korro Bio Inc
15.95 149.75M 0 -81.17M -82.84M -10.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-10 開始されました Oppenheimer Outperform
2024-10-21 開始されました Raymond James Strong Buy
2024-08-14 開始されました William Blair Outperform
2024-03-28 繰り返されました H.C. Wainwright Buy
2024-02-27 開始されました BMO Capital Markets Outperform
2023-12-04 開始されました H.C. Wainwright Buy
2023-11-29 開始されました RBC Capital Mkts Outperform
2023-11-10 開始されました Piper Sandler Overweight
2023-02-15 ダウングレード Chardan Capital Markets Buy → Neutral
2023-02-13 ダウングレード Cowen Outperform → Market Perform
2021-09-22 ダウングレード Goldman Buy → Neutral
2021-01-27 アップグレード JP Morgan Neutral → Overweight
2020-12-22 開始されました B. Riley Securities Buy
2020-07-14 開始されました Oppenheimer Outperform
2020-05-18 ダウングレード JP Morgan Overweight → Neutral
2019-10-28 開始されました Cowen Outperform
2019-10-28 開始されました Goldman Buy
2019-10-28 開始されました JP Morgan Overweight
すべてを表示

Korro Bio Inc (KRRO) 最新ニュース

pulisher
Apr 01, 2025

Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Korro Bio appoints new Chief Scientific Officer - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - Yahoo Finance

Apr 01, 2025
pulisher
Mar 28, 2025

Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

Korro Bio CFO Returns from Medical Leave - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Korro Bio reappoints CFO, names new principal accounting officer - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener

Mar 27, 2025
pulisher
Mar 24, 2025

Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter

Mar 23, 2025
pulisher
Mar 22, 2025

HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Korro Bio Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 19, 2025
pulisher
Mar 18, 2025

Korro Bio, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 15, 2025

FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

FDA grants orphan drug status to Korro’s AATD treatment - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times

Mar 14, 2025
pulisher
Mar 14, 2025

Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Mar 10, 2025
pulisher
Feb 26, 2025

Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

What Will Korro Bio Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan

Feb 26, 2025
pulisher
Feb 23, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 13, 2025

Korro Bio CFO takes medical leave, interim officers appointed - MSN

Feb 13, 2025
pulisher
Feb 11, 2025

Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria

Feb 11, 2025
pulisher
Feb 11, 2025

Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com

Feb 11, 2025
pulisher
Feb 05, 2025

AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com

Feb 05, 2025
pulisher
Feb 01, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 01, 2025
pulisher
Jan 30, 2025

JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Jan 30, 2025
pulisher
Jan 30, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jan 29, 2025
pulisher
Jan 20, 2025

Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World

Jan 20, 2025
pulisher
Jan 18, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat

Jan 18, 2025
pulisher
Jan 13, 2025

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan

Jan 13, 2025

Korro Bio Inc (KRRO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Korro Bio Inc (KRRO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Agarwal Vineet
Chief Financial Officer
Nov 11 '24
Sale
70.00
800
56,000
0
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):